news
Sanofi acquires Translate Bio for mRNA therapeutic development
Sanofi has completed the acquisition of mRNA therapeutics company Translate Bio for a total of approximately $3.2 billion.
List view / Grid view
Sanofi
article
Treating cytokine storms in COVID-19 patients
Enosi Life Science researchers Sir Marc Feldmann, Dr H Michael Shepard and Dr Fiona McCann explain why anti-TNF therapies may be effective in treating COVID-19 associated cytokine storms and other inflammatory conditions.
news
Screening process may enhance mAb drug development, say scientists
Screening potential monoclonal antibody (mAb) drugs on their colloidal stability could eliminate mAbs that do not respond efficiently in solution.
article
COVID-19 and big pharma: what are 15 leading companies doing to develop a coronavirus vaccine?
A new report has revealed the vaccine R&D efforts of 15 of the leading pharmaceutical companies to combat the COVID-19 coronavirus.
news
Job cuts limit cardiovascular and diabetes research and development
Pharmaceutical company, Sanofi, will eliminate jobs in France and Germany and end new in-house cardiology research programmes.
news
Three-in-one antibody may protect from HIV-like virus
A three-pronged antibody has been found to protect from infection with two strains of SHIV, better than individual natural antibodies...
news
Exscientia to collaborate with Sanofi for EUR250mil multiple-product development
Exscientia has agreed a strategic research collaboration, and licence option agreement with Sanofi in the high-interest area of metabolic disease.
news
Sanofi and Lonza partner for biologics production facility
Sanofi and Lonza have entered into a strategic partnership to build and operate a large-scale mammalian cell culture facility for monoclonal antibody production in Visp, Switzerland.
news
Lorenz Mayr joins Drug Discovery 2017 speaker lineup
Lorenz Mayr, esteemed Vice President and Global Head of Biological Reagents and Assay Development at AstraZeneca will be joining the expert speaker lineup for the launch conference on Drug Discovery. The event takes place on 27 and 28 April 2017 in London.
article
How Ketamine could cure depression
Amorsa Therapeutics' CSO, Michael Palfreyman, discusses how the party drug Ketamine can be used to target NMDA receptors and treat depression...
news
Sanofi opens partnering office at Stevenage Bioscience Catalyst
13 April 2016 | By Victoria White, Digital Content Producer
Sanofi has opened a partnering office at Stevenage Bioscience Catalyst to engage and collaborate with the UK's network of bioscience companies and academia...
news
Dr Yong-Jun Lui appointed Sanofi’s Head of Research
29 March 2016 | By Victoria White
Dr Yong-Jun Liu has been appointed as Sanofi’s new Head of Research, Global R&D, effective...
news
IPROVE launches roadmap to bolster vaccine innovation
17 March 2016 | By Victoria White
IPROVE has launched a strategy setting out a vision for vaccine research and innovation in Europe over the next 20 years...
news
Sanofi and DiCE Molecules enter research collaboration
16 March 2016 | By Victoria White
Sanofi and DiCE Molecules have entered a five-year global collaboration to discover potential new therapeutics for up to 12 targets...
news
Sanofi and Warp Drive Bio team up to discover oncology therapeutics and antibiotics
11 January 2016 | By Victoria White
The collaboration will focus on the development of drugs targeting important human oncogenes, including RAS, and new antibiotics targeting Gram-negative bacteria...
